Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had its price target boosted by stock analysts at Morgan Stanley from $101.00 to $130.00 in a note issued to investors on Thursday. The firm currently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price target would suggest a potential downside of 7.13% from the company’s previous close.

Several other equities analysts have also commented on the stock. J P Morgan Chase & Co upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research report on Thursday. B. Riley lowered their price target on shares of Alnylam Pharmaceuticals to $220.00 and set a “buy” rating for the company in a research report on Wednesday. Barclays PLC upped their price target on shares of Alnylam Pharmaceuticals from $127.00 to $158.00 and gave the stock an “overweight” rating in a research report on Wednesday. Credit Suisse Group upped their price target on shares of Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the stock an “outperform” rating in a research report on Friday, November 3rd. Finally, Cowen and Company restated an “outperform” rating and set a $151.00 price target (up previously from $117.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and seventeen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $114.57.

Alnylam Pharmaceuticals (ALNY) traded up $2.30 during trading on Thursday, hitting $139.98. 1,386,900 shares of the stock traded hands, compared to its average volume of 1,120,946. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 8.84. Alnylam Pharmaceuticals has a fifty-two week low of $35.98 and a fifty-two week high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.11). The firm had revenue of $17.10 million for the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The firm’s revenue was up 24.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.21) EPS. equities research analysts predict that Alnylam Pharmaceuticals will post -5.18 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/11/morgan-stanley-increases-alnylam-pharmaceuticals-inc-alny-price-target-to-130-00.html.

In other Alnylam Pharmaceuticals news, EVP Akshay Vaishnaw sold 33,666 shares of the company’s stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the completion of the sale, the executive vice president now directly owns 45,201 shares of the company’s stock, valued at $5,490,113.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, President Barry E. Greene sold 85,316 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $125.00, for a total transaction of $10,664,500.00. The disclosure for this sale can be found here. Insiders sold a total of 215,797 shares of company stock valued at $25,035,072 over the last three months. 4.30% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the business. QS Investors LLC lifted its stake in Alnylam Pharmaceuticals by 59.7% during the second quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 900 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Alnylam Pharmaceuticals by 7.0% during the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 167 shares in the last quarter. Prudential Financial Inc. purchased a new stake in Alnylam Pharmaceuticals during the first quarter valued at about $215,000. CIBC Asset Management Inc purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at about $221,000. Finally, Neuberger Berman Group LLC purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at about $229,000. 94.20% of the stock is owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.